Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a report issued on Monday, August 11th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.96) for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.97) EPS and FY2026 earnings at ($4.12) EPS.
Other equities research analysts also recently issued reports about the company. The Goldman Sachs Group raised Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. UBS Group cut their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Wells Fargo & Company cut their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. JPMorgan Chase & Co. raised their price target on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 3rd. Finally, Morgan Stanley began coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price target for the company. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $59.11.
Get Our Latest Stock Report on Kymera Therapeutics
Kymera Therapeutics Stock Up 2.2%
KYMR stock opened at $40.73 on Thursday. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $53.27. The company has a market cap of $2.91 billion, a PE ratio of -11.74 and a beta of 2.18. The business's 50-day simple moving average is $44.86 and its 200 day simple moving average is $36.48.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%. The firm had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same period last year, the business earned ($0.58) earnings per share. The firm's quarterly revenue was down 55.1% compared to the same quarter last year.
Institutional Trading of Kymera Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Maven Securities LTD acquired a new stake in Kymera Therapeutics during the 2nd quarter worth $2,182,000. Diametric Capital LP acquired a new stake in Kymera Therapeutics during the 2nd quarter worth $288,000. Marshall Wace LLP grew its holdings in Kymera Therapeutics by 33.4% during the 2nd quarter. Marshall Wace LLP now owns 269,284 shares of the company's stock worth $11,752,000 after acquiring an additional 67,384 shares during the period. Kennedy Capital Management LLC acquired a new stake in Kymera Therapeutics during the 2nd quarter worth $211,000. Finally, Invesco Ltd. grew its holdings in Kymera Therapeutics by 13.8% during the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company's stock worth $2,090,000 after acquiring an additional 5,809 shares during the period.
Insider Transactions at Kymera Therapeutics
In related news, Director Elena Ridloff sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 over the last ninety days. 16.01% of the stock is currently owned by insiders.
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.